In 2008, Ali Alsamil started his career as a regulator at Saudi FDA after completing a bachelor's degree in biochemistry. After achieving a master’s degree in biomedical science, Ali works as an assessor of biological drugs at Saudi FDA, and as a voluntary government liaison in a committee of biologics monographs at US pharmacopeia. Currently, Ali is a Ph.D. candidate at Utrecht University, where he is conducting research projects that explore the challenges of assessing the biosimilarity of quality attributes (QAs) as these are central in the development and regulatory review of biologicals and biosimilars. The project also focuses on understanding the role of the QAs in biosimilarity demonstration of biosimilars from a quality and regulatory perspective
How it works
Complete your profile
Take a seat
Meet the others and have fun!
Be nice and share your participation on social media!